Skip to main content

Table 1 Baseline characteristics

From: Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study

 

All patients

Glucocorticoid dose (by 2.5 mg/day increments)

0 mg/day

> 0 mg/day ≤ 2.5 mg/day

> 2.5 mg/day ≤ 5 mg/day

> 5 mg/day ≤ 7.5 mg/day

Variables

N = 175

N = 29

N = 24

N = 92

N = 30

Glucocorticoid, median IQR, mg/day

4.0 [2.0–5.0]

0.0 [0.0–0.0]

1.8 [1.0–2.0]

5.0 [4.0–5.0]

6.0 [6.0–7.0]

Age, median IQR, years

47.0 [37.0–61.0]

44.0 [35.0–61.0]

49.0 [38.0–64.5]

47.5 [36.0–59.0]

47.0 [39.0–58.0]

Sex, female, n (%)

157 (89.7)

24 (82.8)

22 (91.7)

83 (90.2)

28 (93.3)

Damage index (SDI), median IQR, point

0.0 [0.0–1.0]

0.0 [0.0–0.0]

0.0 [0.0–1.0]

0.0 [0.0–1.0]

0.5 [0.0–1.0]

Time since SLE diagnosis, median IQR, year

12.0 [6.0–19.0]

10.0 [5.0–16.0]

11.0 [6.5–19.0]

12.0 [7.0–20.0]

15.0 [7.0–22.0]

Disease activity index (SLEDAI-2 K), median IQR, point

2.0 [0.0–4.0]

2.0 [1.0–4.0]

2.0 [0.5–4.0]

2.0 [0.0–4.0]

2.0 [0.0–2.0]

Hydroxychloroquine, n (%)

46 (26.3)

3 (10.3)

5 (20.8)

24 (26.1)

14 (46.7)

Number of Immunosuppressants

 1, n (%)

78 (44.6)

7 (24.1)

6 (25.0)

50 (54.3)

15 (50.0)

 2, n (%)

15 (8.6)

3 (10.3)

2 (8.3)

5 (5.4)

5 (16.7)

Immunosuppressants

 Cyclophosphamide, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

 Mycophenolate mofetil, n (%)

15 (8.6)

2 (6.9)

2 (8.3)

7 (7.6)

4 (13.3)

 Mizoribine, n (%)

12 (6.9)

1 (3.4)

3 (12.5)

6 (6.5)

2 (6.7)

 Methotrexate, n (%)

3 (1.7)

1 (3.4)

0 (0.0)

1 (1.1)

1 (3.3)

 Azathioprine, n (%)

15 (8.6)

0 (0.0)

1 (4.2)

11 (12.0)

3 (10.0)

 Tacrolimus, n (%)

53 (30.3)

8 (27.6)

3 (12.5)

28 (30.4)

14 (46.7)

 Cyclosporine, n (%)

10 (5.7)

1 (3.4)

1 (4.2)

7 (7.6)

1 (3.3)

Antipsychotics, n (%)

10 (5.7)

0 (0.0)

2 (8.3)

5 (5.4)

3 (10.0)

History of diagnosis

 Neuropsychiatric lupus, n (%)

6 (3.4)

2 (6.9)

1 (4.2)

2 (2.2)

1 (3.3)

 Lupus nephritis, n (%)

38 (21.7)

6 (20.7)

3 (12.5)

23 (25.0)

6 (20.0)

  1. Note: Values are presented as the median and numbers in brackets indicate interquartile ranges for continuous variables. Categorical variables are presented as the number and (in parentheses) the percentage of patients divided into four groups by 2.5 mg increments in glucocorticoid dose
  2. IQR interquartile range, SDI Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000